The Evolution of HTA in Emerging Markets Health-Care ... - TREE

More documents

Recommendations

Info

OHE Consulting Report for PhRMA 5 January 2011 position papers and other policy articles available in the health economic literature. We were asked not to assume the use of HTA is an appropriate policy response for payers, but, conditional on a payer decision on the use of HTA, exploring how one can understand types of HTA, and their strengths and weaknesses, including in different contexts An essential component of this part of our work has been to undertake an interview programme in the three countries to underpin the literature review and analysis. We have chosen to contact: Policy people involved in health services based in the three countries; Academics familiar with the three countries; Key pharmaceutical industry respondents from both global offices and national affiliates with a direct experience of the three countries, or key individuals from local trade associations or PhRMA groups. In defining our list of interviewees, we relied on our already established network of contacts in many companies to help us in identifying the names of appropriate ‘points of entry’ in other organisations. We ensured the ‘appropriateness’ of the selected interviewees in discussions with the Project Steering Group. We contacted potential interviewees initially by email, followed up by a telephone call to try and book a time for a later telephone interview. As an incentive to participate in the interview, we offered to send to all respondents a summary of some elements of the report and for some non-government interviewees we offered honoraria. We intended to obtain a maximum of 18 interviews – around two representatives of each of the categories listed above (i.e. policy people, academic experts and industry people) for each country – recognising that the number of interviewees might well be slightly lower, considering that for certain countries the local expert may represent both the academic and the policy side, or that some academics will have expertise on more than one country. In practice we obtained 19 and the list of potential interviewees is set out in Annex 5. 4.2 Project Steering Group We have worked with the Project Steering Group established by PhRMA during the course of the project. We held a meeting by telecon on 21st January 2010 shortly after initiation of the project. On subsequent occasions we have used the Steering Group for comment on our Interim Report issued on 5 th June 2010 and on the individual country summaries issued on 18 th October 2010. We are now seeking feedback from Project Steering Group on this draft of the Final Report. 22
OHE Consulting Report for PhRMA 5 January 2011 In addition, we have liaised with Stephanie Lane of PhRMA as the single point of contact for the duration of the project. We would like to thank Stephanie for her support and advice during the project. 4.3 Deliverables The Final Report is intended to enable PhRMA to: (1) develop its public policy positions within a credible framework relating any potential use of HTA proposed by payers to the evolution of health care systems; (2) develop an appropriate response within this framework to engage and shape HTA when it is put forward by a payer in these three countries; and (3) begin to build a network of contacts within the three countries to help take its approach forward. In addition, as set out in the proposal, we will produce a Working Paper based on sections 4, 5, and 6 of this Report which could be put in the public domain. No material relating to possible PhRMA policy options would be included in any Working Paper. 23
Page 1 and 2: Consulting Report 1 The Evolution
Page 3 and 4: OHE Consulting Report for PhRMA 5 J
Page 21: OHE Consulting Report for PhRMA 5 J
Page 73 and 74:
OHE Consulting Report for PhRMA 5 J
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119:
show all

The Evolution of HTA in Emerging Markets Health-Care ... - TREE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?